Host: | Mouse |
Applications: | IHC-P |
Reactivity: | Human |
Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description : | Mouse monoclonal antibody anti-b-catenin (Full length) is suitable for use in Immunohistochemistry research applications. |
Clonality : | Monoclonal |
Clone ID : | ZM13 |
Conjugation: | Unconjugated |
Isotype: | IgG2b/Kappa |
Formulation: | Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
Purification: | Affinity purified |
Dilution Range: | 1:100‐200 |
Storage Instruction: | Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C. |
Immunogen Region: | Full length |
Specificity: | Positive control: Fibromatosis or transitional cell carcinoma |
Immunogen: | Recombinant full-length human beta-catenin (CTNNB1) protein |
Background | Beta-catenin associates with the cytoplasmic portion of E-cadherin, which is necessary for the function of E-cadherin as an adhesion molecule. In normal tissues, beta-catenin is localized to the membrane of epithelial cells, consistent with its role in the cell adhesion complex. In breast ductal neoplasia, beta-catenin is usually localized in cellular membranes. However, in lobular neoplasia, a marked redistribution of beta-catenin throughout the cytoplasm results in a diffuse cytoplasmic pattern. Immuno-staining of beta-catenin and E-cadherin helps in the accurate identification of ductal and lobular neoplasms, including a distinction between low-grade ductal carcinoma in situ (DCIS) and lobular carcinoma. Additionally, some rectal and gastric adenocarcinomas demonstrate diffuse cytoplasmic beta-catenin staining and a lack of membranous staining, mimicking the staining pattern observed with lobular breast carcinomas. |
Information sourced from Uniprot.org